Professor David Heal will be co-presenting two posters at the American College of Neuropsychopharmacology (ACNP) 59th Annual Meeting - Virtual Conference to be held from 6th to 9th December, 2020.
The posters report new findings on two late-stage novel drug-candidates: Centafadine, which is Otsuka Pharmaceuticals’ drug-candidate for the treatment of ADHD, and SEP-363856, which is Sunovion Pharmaceuticals’ non-D2, non-5-HT2A drug-candidate for the treatment of schizophrenia.
T149: Poster session II; Tuesday 8th December 2.00 – 3.30 pm (CET) (15.00-16.30h [EST] and
20.00-21.30h [UK time]).
SEP-363856, a Novel TAAR1 Agonist, Lacks Abuse Liability in Preclinical Models and Attenuates Cocaine Cue-Induced Relapse in Rats.
Colleen Synan, Carrie Bowen, David Heal, Christelle Froger-Colleaux, Patrick M. Beardsley, Una Campbell.
W51: Poster session II1; Wednesday 9th December 3.30 – 5.00 pm (CET) (16.30-18.00h [EST] and 21.30-23.00h [UK time]).
Evaluation of the Discriminative and Reinforcing Potential of Centanafadine and Reference Comparator ADHD Drugs by Drug-Discrimination and Intravenous Self-Administration Testing in Rats.
David Heal, Helen Rowley, Sharon Smith, Reem Elbekai.